

## 6. Annexes

### 6.1 Bibliographie

1. Fields Virology (Knipe, Fields Virology)-2 Volume Set. Sixth, 2-volume set edition. Philadelphia, PA: LWW; 2013. 2664 p.
2. Davison AJ. Overview of classification. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis [Internet]. Cambridge: Cambridge University Press; 2007 [cited 2016 Oct 20]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK47406/>
3. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: Expert Consult Premium Edition - Enhanced Online Features and Print. 7 edition. Philadelphia, PA: Churchill Livingstone; 2009. 4320 p.
4. Death for CMV [Internet]. Science for Scientists. 2012 [cited 2016 Nov 16]. Available from: <https://scienceforscientists.wordpress.com/2012/06/21/death-for-cmv/>
5. Britt W. CHAPTER 23 - Cytomegalovirus A2 - Remington, Jack S. In: Klein JO, Wilson CB, Nizet V, Maldonado YA, editors. Infectious Diseases of the Fetus and Newborn (Seventh Edition) [Internet]. Philadelphia: W.B. Saunders; 2011 [cited 2016 Oct 26]. p. 706–55. Available from: <http://www.sciencedirect.com/science/article/pii/B9781416064008000237>
6. Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006 Nov 1;43(9):1143–51.
7. Stagno S, Whitley RJ. Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and Epstein-Barr virus infections. N Engl J Med. 1985 Nov 14;313(20):1270–4.
8. Stowell JD, Forlin-Passoni D, Din E, Radford K, Brown D, White A, et al. Cytomegalovirus survival on common environmental surfaces: opportunities for viral transmission. J Infect Dis. 2012 Jan 15;205(2):211–4.
9. Cannon MJ. Congenital cytomegalovirus (CMV) epidemiology and awareness. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2009 Dec;46 Suppl 4:S6–10.
10. Revello MG, Gerna G. Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications. Rev Med Virol. 2010 Jan 18;20(3):136–55.
11. Bissinger AL, Sinzger C, Kaiserling E, Jahn G. Human cytomegalovirus as a direct pathogen: correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. J Med Virol. 2002 Jun;67(2):200–6.
12. Marshall BC, Adler SP. The frequency of pregnancy and exposure to cytomegalovirus infections among women with a young child in day care. Am J Obstet Gynecol. 2009 Feb;200(2):163.e1–5.
13. Soper DE. Congenital Cytomegalovirus Infection: An Obstetrician's Point of View. Clin Infect Dis. 2013 Dec 15;57(suppl 4):S171–3.
14. Pass RF, Hutto SC, Reynolds DW, Polhill RB. Increased frequency of cytomegalovirus infection in children in group day care. Pediatrics. 1984 Jul;74(1):121–6.
15. al GM et. Congenital cytomegalovirus infection: review of the epidemiology and outcome. - PubMed - NCBI [Internet]. [cited 2016 Oct 11]. Available from: <https://crypto.unil.ch/pubmed/,DanaInfo=www.ncbi.nlm.nih.gov,SSL+11961482>
16. Ko J-H, Peck KR, Lee WJ, Lee JY, Cho SY, Ha YE, et al. Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015 Mar 15;60(6):e20–6.
17. MACP GLMM, MD JEB, MD RD. Principles and Practice of Infectious Diseases: 2-Volume Set. 6 edition. New York: Churchill Livingstone; 2004. 4016 p.
18. Cytomegalovirus (CMV) infection nuclear inclusions | Medical Laboratories [Internet]. [cited 2016 Oct 27]. Available from: <http://www.medical-labs.net/cytomegalovirus-cmv-infection-nuclear-inclusions-2476/>
19. Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol. 1996 Dec;77 ( Pt 12):3099–102.
20. Nigro G, Anceschi MM, Cosmi EV, Congenital Cytomegalic Disease Collaborating Group. Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection. BJOG Int J Obstet Gynaecol. 2003 Jun;110(6):572–7.
21. Gehrz RC, Christianson WR, Linner KM, Conroy MM, McCue SA, Balfour HH. Cytomegalovirus-specific humoral and cellular immune responses in human pregnancy. J Infect Dis. 1981 Mar;143(3):391–5.
22. Griffiths PD. Cytomegalovirus. In: Microbiology AJZ of M, Virology JEBE of C, Pattison JR, Virology PDG of, Director BDSE, editors. Principles and Practice of Clinical Virology [Internet]. John Wiley & Sons, Ltd; 2004 [cited 2016 Oct 27]. p. 85–122. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/0470020970.ch2C/summary>
23. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev. 2002 Oct;15(4):680–715.
24. Sadler TW, Langman J. Langman's medical embryology. Philadelphia: Wolters Kluwer

- Health/Lippincott Williams & Wilkins; 2012.
25. Boppana SB, Ross SA, Shimamura M, Palmer AL, Ahmed A, Michaels MG, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. *N Engl J Med*. 2011 Jun 2;364(22):2111–8.
  26. Cannon MJ, Griffiths PD, Aston V, Rawlinson WD. Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit? *Rev Med Virol*. 2014 Sep;24(5):291–307.
  27. Ross SA, Novak Z, Pati S, Boppana SB. Diagnosis of Cytomegalovirus Infections. *Infect Disord Drug Targets*. 2011;11(5):466.
  28. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “Silent” Global Burden of Congenital Cytomegalovirus. *Clin Microbiol Rev*. 2013 Jan 1;26(1):86–102.
  29. Diseases AC on I. Red Book, 29th Edition (2012). 2012.
  30. Vochem M, Hamprecht K, Jahn G, Speer CP. Transmission of cytomegalovirus to preterm infants through breast milk. *Pediatr Infect Dis J*. 1998 Jan;17(1):53–8.
  31. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. *Rev Med Virol*. 2007 Sep 1;17(5):355–63.
  32. Lanzieri TM, Dollard SC, Bialek SR, Grosse SD. Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries. *Int J Infect Dis*. 2014 May;22:44–8.
  33. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. *Rev Med Virol*. 2007 Jul;17(4):253–76.
  34. Gabrielli L, Bonasoni MP, Lazzarotto T, Lega S, Santini D, Foschini MP, et al. Histological findings in foetuses congenitally infected by cytomegalovirus. *J Clin Virol*. 2009 Dec;46:S16–21.
  35. Gaytán MA, Steegers EAP, Semmekrot BA, Merkus HMMW, Galama JMD. Congenital cytomegalovirus infection: review of the epidemiology and outcome. *Obstet Gynecol Surv*. 2002 Apr;57(4):245–56.
  36. Adler SP. Screening for Cytomegalovirus during Pregnancy. *Infect Dis Obstet Gynecol*. 2011;2011:1–9.
  37. La Torre R, Nigro G, Mazzocco M, Best AM, Adler SP. Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2006 Oct 15;43(8):994–1000.
  38. Benoist G, Salomon L, Jacquemard F, Daffos F, Ville Y. The prognostic value of ultrasound abnormalities and biological parameters in blood of fetuses infected with cytomegalovirus. *BJOG Int J Obstet Gynaecol*. 2008 Jun;115(7):823–9.
  39. Bodéus M, Kabamba-Mukadi B, Zech F, Hubinont C, Bernard P, Goubaud P. Human cytomegalovirus in utero transmission: Follow-up of 524 maternal seroconversions. *J Clin Virol*. 2010 Feb;47(2):201–2.
  40. Boppana SB, Ross SA, Fowler KB. Congenital Cytomegalovirus Infection: Clinical Outcome. *Clin Infect Dis*. 2013 Dec 15;57(suppl 4):S178–81.
  41. Benoist G, Leruez-Ville M, Magny JF, Jacquemard F, Salomon LJ, Ville Y. Management of Pregnancies with Confirmed Cytomegalovirus Fetal Infection. *Fetal Diagn Ther*. 2013;33(4):203–14.
  42. Coll O, Benoist G, Ville Y, Weisman LE, Botet F, Anceschi MM, et al. Guidelines on CMV congenital infection. *J Perinat Med*. 2009;37(5):433–45.
  43. Colugnati FAB, Staras SAS, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. *BMC Infect Dis*. 2007;7:71.
  44. Ahlfors K, Ivarsson SA, Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. *Scand J Infect Dis*. 1999;31(5):443–57.
  45. Nigro G, Adler SP. Cytomegalovirus infections during pregnancy: *Curr Opin Obstet Gynecol*. 2011 Apr;23(2):123–8.
  46. Hui L, Wood G. Perinatal outcome after maternal primary cytomegalovirus infection in the first trimester: a practical update and counseling aid: Perinatal outcome after maternal CMV infection. *Prenat Diagn*. 2015 Jan;35(1):1–7.
  47. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. *J Pediatr*. 2004 Oct;145(4):485–91.
  48. Leruez-Ville M, Ville Y. Infection à cytomegalovirus pendant la grossesse : enjeux et prise en charge. *Presse Médicale*. 2014 Jun;43(6):683–90.
  49. Stagno S, Pass RF, Dworsky ME, Henderson RE, Moore EG, Walton PD, et al. Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection. *N Engl J Med*. 1982 Apr 22;306(16):945–9.
  50. Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP. New advances in the diagnosis of congenital cytomegalovirus infection. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2008 Mar;41(3):192–7.
  51. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. *N Engl J Med*. 1992 Mar 5;326(10):663–7.
  52. Duryea EL, Sánchez PJ, Sheffield JS,

- Jackson GL, Wendel GD, McElwee BS, et al. Maternal human immunodeficiency virus infection and congenital transmission of cytomegalovirus. *Pediatr Infect Dis J.* 2010 Oct;29(10):915–8.
53. Hadar E, Yoge Y, Melamed N, Chen R, Amir J, Pardo J. Periconceptional cytomegalovirus infection: pregnancy outcome and rate of vertical transmission. *Prenat Diagn.* 2010 Dec;30(12-13):1213–6.
54. Zalel Y, Gilboa Y, Berkenshtat M, Yoeli R, Auslander R, Achiron R, et al. Secondary cytomegalovirus infection can cause severe fetal sequelae despite maternal preconceptional immunity. *Ultrasound Obstet Gynecol.* 2008 Apr;31(4):417–20.
55. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. *N Engl J Med.* 2001 May 3;344(18):1366–71.
56. Ahlfors K, Ivarsson SA, Harris S. Secondary maternal cytomegalovirus infection--A significant cause of congenital disease. *Pediatrics.* 2001 May;107(5):1227–8.
57. Townsend CL, Forsgren M, Ahlfors K, Ivarsson S-A, Tookey PA, Peckham CS. Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2013 May;56(9):1232–9.
58. Ross SA, Fowler KB, Ashrith G, Stagno S, Britt WJ, Pass RF, et al. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. *J Pediatr.* 2006 Mar;148(3):332–6.
59. Yamamoto AY, Mussi-Pinhata MM, Isaac M de L, Amaral FR, Carvalheiro CG, Aragon DC, et al. Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. *Pediatr Infect Dis J.* 2011 Dec;30(12):1043–6.
60. Picone O, Vauloup-Fellous C, Cordier AG, Guittot S, Senat MV, Fuchs F, et al. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome: Outcome of maternal CMV infection during pregnancy. *Prenat Diagn.* 2013 Aug;33(8):751–8.
61. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. *JAMA.* 1986 Oct 10;256(14):1904–8.
62. Gindes L, Teperberg-Oikawa M, Sherman D, Pardo J, Rahav G. Congenital cytomegalovirus infection following primary maternal infection in the third trimester. *BJOG Int J Obstet Gynaecol.* 2008 Jun;115(7):830–5.
63. Bodéus M, Hubinont C, Goubau P. Increased risk of cytomegalovirus transmission in utero during late gestation. *Obstet Gynecol.* 1999 May;93(5 Pt 1):658–60.
64. Enders G, Daiminger A, Bäder U, Exler S, Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. *J Clin Virol.* 2011 Nov;52(3):244–6.
65. Revello MG, Zavattini M, Sarasini A, Percivalle E, Simoncini L, Gerna G. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. *J Infect Dis.* 1998 May;177(5):1170–5.
66. Pass RF, Fowler KB, Boppana SB, Britt WJ, Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: Symptoms at birth and outcome. *J Clin Virol.* 2006 Feb;35(2):216–20.
67. Enders G, Bäder U, Lindemann L, Schalasta G, Daiminger A. Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. *Prenat Diagn.* 2001 May;21(5):362–77.
68. Guerra B, Simonazzi G, Banfi A, Lazzarotto T, Farina A, Lanari M, et al. Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers. *Am J Obstet Gynecol.* 2007 Mar;196(3):221.e1–221.e6.
69. Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2011 Sep;17(9):1285–93.
70. Revello MG, Fabbri E, Furione M, Zavattini M, Lilleri D, Tassis B, et al. Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: A 20-year experience. *J Clin Virol.* 2011 Apr;50(4):303–7.
71. Lazzarotto T, Spezzacatena P, Pradelli P, Abate DA, Varani S, Landini MP. Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. *Clin Diagn Lab Immunol.* 1997 Jul;4(4):469–73.
72. Kanengisser-Pines B, Hazan Y, Pines G, Appelman Z. High cytomegalovirus IgG avidity is a reliable indicator of past infection in patients with positive IgM detected during the first trimester of pregnancy. *J Perinat Med [Internet].* 2009 Jan 1 [cited 2015 Aug 24];37(1). Available from: <http://www.degruyter.com/view/j/jpme.2009.37.issue-1/jpm.2009.012/jpm.2009.012.xml>
73. Grangeot-Keros L, Mayaux MJ, Lebon P, Freymuth F, Eugene G, Stricker R, et al. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. *J Infect Dis.* 1997 Apr;175(4):944–6.
74. Bonalumi S, Trapanese A, Santamaria A,

- D'Emidio L, Mobili L. Cytomegalovirus infection in pregnancy: review of the literature. *J Prenat Med.* 2011;5(1):1.
75. Lipitz S, Yagel S, Shalev E, Achiron R, Mashiach S, Schiff E. Prenatal diagnosis of fetal primary cytomegalovirus infection. *Obstet Gynecol.* 1997 May;89(5 Pt 1):763–7.
76. Avidor B, Efrat G, Weinberg M, Kra-oz Z, Satinger J, Mitrani-Rosenbaum S, et al. Insight into the intrinsic sensitivity of the PCR assay used to detect CMV infection in amniotic fluid specimens. *J Clin Virol Off Publ Pan Am Soc Clin Virol.* 2004 Apr;29(4):260–70.
77. Guerra B, Lazzarotto T, Quarta S, Lanari M, Bovicelli L, Nicolosi A, et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. *Am J Obstet Gynecol.* 2000 Aug;183(2):476–82.
78. Gouarin S, Gault E, Vabret A, Cointe D, Rozenberg F, Grangeot-Keros L, et al. Real-Time PCR Quantification of Human Cytomegalovirus DNA in Amniotic Fluid Samples from Mothers with Primary Infection. *J Clin Microbiol.* 2002 May 1;40(5):1767–72.
79. Bodéus M, Hubinont C, Bernard P, Bouckaert A, Thomas K, Goubau P. Prenatal diagnosis of human cytomegalovirus by culture and polymerase chain reaction: 98 pregnancies leading to congenital infection. *Prenat Diagn.* 1999 Apr;19(4):314–7.
80. Liesnard C, Donner C, Brancart F, Gossein F, Delforge ML, Rodesch F. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. *Obstet Gynecol.* 2000 Jun;95(6 Pt 1):881–8.
81. Goegebuer T, Van Meensel B, Beuselinck K, Cossey V, Van Ranst M, Hanssens M, et al. Clinical predictive value of real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples. *J Clin Microbiol.* 2009 Mar;47(3):660–5.
82. Revello MG, Furione M, Zavattoni M, Tassis B, Nicolini U, Fabbri E, et al. Human cytomegalovirus (HCMV) DNAemia in the mother at amniocentesis as a risk factor for iatrogenic HCMV infection of the fetus. *J Infect Dis.* 2008 Feb 15;197(4):593–6.
83. Azam A-Z, Vial Y, Fawer C-L, Zufferey J, Hohlfeld P. Prenatal diagnosis of congenital cytomegalovirus infection. *Obstet Gynecol.* 2001;97(3):443–8.
84. Revello MG, Zavattoni M, Sarasini A, Baldanti F, De Julio C, De-Giuli L, et al. Prenatal diagnostic and prognostic value of human cytomegalovirus load and IgM antibody response in blood of congenitally infected fetuses. *J Infect Dis.* 1999;180(4):1320–3.
85. Fabbri E, Revello M, Furione M, Zavattoni M, Lilleri D, Tassis B, et al. Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood: Prognostic markers of congenital HCMV disease. *BJOG Int J Obstet Gynaecol.* 2011 Mar;118(4):448–56.
86. Guerra B, Simonazzi G, Puccetti C, Lanari M, Farina A, Lazzarotto T, et al. Ultrasound prediction of symptomatic congenital cytomegalovirus infection. *Am J Obstet Gynecol.* 2008 Apr;198(4):380.e1–7.
87. Ville Y. The megalovirus. *Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol.* 1998 Sep;12(3):151–3.
88. Gabbay-Benziv R, Gabbay-Ben Ziv R, Yogeve Y, Peled Y, Amir J, Pardo J. Congenital cytomegalovirus infection following antenatal negative diagnostic amniotic fluid analysis - a single center experience. *J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet.* 2012 Sep;25(9):1787–90.
89. Grangeot-Keros L, Cointe D. Infections virales et grossesse: apport des prélèvements amniotiques et sanguins. *Gynécologie Obstétrique Fertil.* 2001;29(12):894–9.
90. Rahav G. Congenital cytomegalovirus infection--a question of screening. *Isr Med Assoc J IMAJ.* 2007 May;9(5):392–4.
91. team EC for DP and C (ECDC)-HCU-E editorial. Prevention of congenital and perinatal infections [Internet]. 2009 [cited 2016 Oct 12]. Available from: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19131>
92. Carlson A, Norwitz ER, Stiller RJ. Cytomegalovirus Infection in Pregnancy: Should All Women Be Screened? *Rev Obstet Gynecol.* 2010;3(4):172–9.
93. SALAMON PR. Recommandations de l'Anaes. *J Gynecol Obstet Biol Reprod.* 2005;34(2):170–4.
94. Walker SP, Palma-Dias R, Wood EM, Shekleton P, Giles ML. Cytomegalovirus in pregnancy: to screen or not to screen. *BMC Pregnancy Childbirth.* 2013;13(1):96.
95. Vauloup-Fellous C, Picone O, Cordier A-G, Parent-du-Châtelet I, Senat M-V, Frydman R, et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. *J Clin Virol Off Publ Pan Am Soc Clin Virol.* 2009 Dec;46 Suppl 4:S49–53.
96. Picone O, Vauloup-Fellous C, Cordier A-G, Parent Du Châtelet I, Senat M-V, Frydman R, et al. A 2-year study on cytomegalovirus infection during pregnancy in a French hospital. *BJOG Int J Obstet Gynaecol.* 2009 May 1;116(6):818–23.
97. Ross DS, Victor M, Sumartojo E, Cannon MJ. Women's knowledge of congenital cytomegalovirus: results from the 2005 HealthStyles survey. *J Womens Health.* 2008 Jun;17(5):849–58.
98. Group JCCIIFTS, others. A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection. *J Reprod Immunol.*

- 2012;95(1):73–9.
99. Wagner N, Kagan KO, Haen S, Schmidt S, Yerlikaya G, Maden Z, et al. Effective management and intrauterine treatment of congenital cytomegalovirus infection: review article and case series. *J Matern Fetal Neonatal Med*. 2014 Jan;27(2):209–14.
100. Nigro G, Adler SP, La Torre R, Best AM, Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. *N Engl J Med*. 2005 Sep 29;353(13):1350–62.
101. Moxley K, Knudtson EJ. Resolution of hydrops secondary to cytomegalovirus after maternal and fetal treatment with human cytomegalovirus hyperimmune globulin. *Obstet Gynecol*. 2008 Feb;111(2 Pt 2):524–6.
102. Moise KJ, Wolfe H. Treatment of second trimester fetal cytomegalovirus infection with maternal hyperimmune globulin. *Prenat Diagn*. 2008 Mar;28(3):264–5.
103. Nigro G, La Torre R, Pentimalli H, Taverna P, Lituania M, de Tejada BM, et al. Regression of fetal cerebral abnormalities by primary cytomegalovirus infection following hyperimmunoglobulin therapy. *Prenat Diagn*. 2008 Jun;28(6):512–7.
104. Visentin S, Manara R, Milanese L, Da Roit A, Forner G, Salviato E, et al. Early Primary Cytomegalovirus Infection in Pregnancy: Maternal Hyperimmunoglobulin Therapy Improves Outcomes Among Infants at 1 Year of Age. *Clin Infect Dis*. 2012 Aug 15;55(4):497–503.
105. Revello MG, Lazzarotto T, Guerra B, Spinallo A, Ferrazzi E, Kustermann A, et al. A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus. *N Engl J Med*. 2014 Apr 3;370(14):1316–26.
106. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, et al. Vaccine prevention of maternal cytomegalovirus infection. *N Engl J Med*. 2009 Mar 19;360(12):1191–9.
107. Jacquemard F, Yamamoto M, Costa J-M, Romand S, Jaqz-Aigrain E, Dejean A, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. *BJOG Int J Obstet Gynaecol*. 2007 Sep;114(9):1113–21.
108. Leruez-Ville M, Ghout I, Bussières L, Stirnemann J, Magny J-F, Couderc S, et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. *Am J Obstet Gynecol*. 2016 Oct;215(4):462.e1–462.e10.
109. Kimberlin DW, Lin C-Y, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. *J Pediatr*. 2003 Jul;143(1):16–25.
110. Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. *N Engl J Med*. 2015 Mar 5;372(10):933–43.
111. Jeon J, Victor M, Adler SP, Arwady A, Demmler G, Fowler K, et al. Knowledge and awareness of congenital cytomegalovirus among women. *Infect Dis Obstet Gynecol*. 2006;2006:80383.
112. Lazzarotto T, Gabrielli L, Foschini MP, Lanari M, Guerra B, Eusebi V, et al. Congenital cytomegalovirus infection in twin pregnancies: viral load in the amniotic fluid and pregnancy outcome. *Pediatrics*. 2003;112(2):e153–7.
113. Picone O, Costa J-M, Leruez-Ville M, Ernault P, Olivi M, Ville Y. Cytomegalovirus (CMV) glycoprotein B genotype and CMV DNA load in the amniotic fluid of infected fetuses. *Prenat Diagn*. 2004 Dec 15;24(12):1001–6.
114. Lipitz S, Hoffmann C, Feldman B, Tepperberg-Dikawa M, Schiff E, Weisz B. Value of prenatal ultrasound and magnetic resonance imaging in assessment of congenital primary cytomegalovirus infection. *Ultrasound Obstet Gynecol*. 2010 Dec;36(6):709–17.
115. Lipitz S, Yinon Y, Malinge G, Yagel S, Levit L, Hoffman C, et al. Risk of cytomegalovirus-associated sequelae in relation to time of infection and findings on prenatal imaging: Prenatal imaging and CMV-related sequelae. *Ultrasound Obstet Gynecol*. 2013 May;41(5):508–14.
116. Picone O, Costa J-M, Dejean A, Ville Y. Is fetal gender a risk factor for severe congenital cytomegalovirus infection? *Prenat Diagn*. 2005 Jan;25(1):34–8.
117. Daiminger A, Bäder U, Enders G. Pre- and periconceptional primary cytomegalovirus infection: risk of vertical transmission and congenital disease. *BJOG Int J Obstet Gynaecol*. 2005 Feb;112(2):166–72.
118. Pass RF, Stagno S, Myers GJ, Alford CA. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. *Pediatrics*. 1980 Nov;66(5):758–62.
119. Dreher AM, Arora N, Fowler KB, Novak Z, Britt WJ, Boppana SB, et al. Spectrum of Disease and Outcome in Children with Symptomatic Congenital Cytomegalovirus Infection. *J Pediatr*. 2014 Apr;164(4):855–9.
120. Lazzarotto T, Varani S, Guerra B, Nicolosi A, Lanari M, Landini MP. Prenatal indicators of congenital cytomegalovirus infection. *J Pediatr*. 2000 Jul;137(1):90–5.
121. Revello MG, Zavattoni M, Baldanti F, Sarasini A, Paolucci S, Gerna G. Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 1999 Sep;14(1):57–66.
122. Boppana SB, Fowler KB, Pass RF, Rivera LB, Bradford RD, Lakeman FD, et al. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. *J Pe-*

- diatr. 2005 Jun;146(6):817–23.
123. VC E. Viral dynamics during active cytomegalovirus infection and pathology. - PubMed - NCBI [Internet]. [cited 2016 Oct 11]. Available from:  
<https://crypto.unil.ch/pubmed/,DanaInfo=www.ncbi.nlm.nih.gov,SSL+10702724>
124. Lanari M, Lazzarotto T, Venturi V, Papa I, Gabrielli L, Guerra B, et al. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. *Pediatrics*. 2006 Jan;117(1):e76–83.
125. Romanelli RM de C, Magny JF, Jacquemard F. Prognostic markers of symptomatic congenital cytomegalovirus infection. *Braz J Infect Dis Off Publ Braz Soc Infect Dis*. 2008 Feb;12(1):38–43.
126. Revello MG, Zavattoni M, Furione M, Baldanti F, Gerna G. Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses. *J Clin Microbiol*. 1999 Oct;37(10):3350–2.
127. Bale JF, Blackman JA, Sato Y. Outcome in children with symptomatic congenital cytomegalovirus infection. *J Child Neurol*. 1990 Apr;5(2):131–6.
128. Simonazzi G, Curti A, Murano P, Cervi F, Contoli M, Lazzarotto T, et al. Congenital cytomegalovirus infection and small for gestational age infants: SGA infants in congenital CMV infection. *Prenat Diagn*. 2014 Aug;34(8):765–9.
129. Fowler KB, Pass RF. Risk factors for congenital cytomegalovirus infection in the offspring of young women: exposure to young children and recent onset of sexual activity. *Pediatrics*. 2006 Aug;118(2):e286–92.
130. Revello MG, Zavattoni M, Furione M, Lilleri D, Gorini G, Gerna G. Diagnosis and outcome of preconceptual and periconceptual primary human cytomegalovirus infections. *J Infect Dis*. 2002 Aug 15;186(4):553–7.

## 6.2 Compléments

34

Classification		Signes pré-nataux			
outcome	sous groupe	ID	Critères laboratoires	Critères Ultrasons	Signes néonataux
IF Issue favorable n= 17 (59%)	Groupe A n=1 (4%)	1	-	-	IMG
		2	-	-	-
		3	-	-	-
		4	-	-	-
		5	-	-	SGA <sup>a</sup>
		6	-	-	-
		7	-	-	-
		8	-	-	-
		9	-	-	SGA <sup>a</sup>
		10	-	-	-
ID Issue défavorable n=11 (41%)	Groupe B n=9 (33%)	11	anémie	-	-
		12	ASAT↑	-	-
		13	-	hyperéchogénicité périventriculaire transitoire	-
		14	ASAT↑	-	-
		15	ASAT↑	-	-
	Groupe C n=5 (18%)	16	leucocytose, GGT ↑	-	-
		17	-	-	pétéchies, ASAT↑, GGT↑ rétinite
	Groupe D n=1 (4%)	18	-	-	-
		19	-	polyhydramnios	déficit auditif D <sup>b</sup>
	Groupe E n=2 (7%)	20	anémie et thrombocytopénie sévère	-	IMG
		21	anémie, thrombocytopénie sévère. Leucocytose et ASAT↑	calcifications cérébrales et hyperéchogénicité intestinale	IMG
		22	thrombocytopénie sévère, ASAT ↑	-	IMG
		23	thrombocytopénie modérée, ASAT ↑	-	IMG
		24	thrombopénie modérée	hyperéchogénicité périventriculaire, nodules hépatiques, anses intestinales hyperéchogènes	IMG
		25	thrombocytopénie modérée, GGT ↑	-	IMG
		26	leucocytose avec monocytose	-	IMG
		27	thrombocytopénie sévère, ASAT ↑	hyperéchogénicité des anses intestinales, oligoamnios	IMG

<sup>a</sup> poids <10ème percentile à la naissance en fonction de l'âge gestationnel

<sup>b</sup> seuil PEA > 40 dB à D

ASAT, aspartate aminotransférase; GGT, gamma-glutamyltranspeptidase; SGA, small for gestational age/faible poids pour l'âge gestationnel; IMG, interruption médicale de grossesse

Annexe 1 : Tableau récapitulatif de la classification fœtale, ainsi que des signes/symptômes présentés en pré/postnatal

classification								
outcome	sous groupe	ID	Age <sup>a</sup> de la grossesse au moment de l'amniocentèse	Intervalle entre l'infection maternelle présumé et l'amniocentèse	Charge virale dans le liquide amniotique	Age <sup>a</sup> de la grossesse au moment de la cordo centèse	Charge virale dans le sang fœtal	
IF Issue favorable n=16 (59%)	<b>Groupe A</b>							
	n=1 (4%)	1	16.9	11.9	1.73E+04	17.7	1.32E+05	
	<b>Groupe B</b>							
	n=9 (33%)	2	20.0	17.0	6.46E+05	20.7	3.50E+02	
		3	21.7	14.7	5.06E+05	21.7	4.30E+03	
		4	20.3	20.3	3.00E+06	20.6	3.65E+02	
		5	23.3	6.3	9.00E+06	23.9	1.44E+05	
		6	20.9	7.9	1.70E+08	21.9	6.40E+04	
		7	23.6	23.6	1.53E+06	23.6	1.35E+04	
		8	25.9	16.9	1.50E+07	26.4	5.33E+03	
		9	20.4	20.4	4.48E+06	20.4	3.87E+07	
		10	15.6	8.6	9.30E+04	19.7	1.19E+04	
	<b>Groupe C</b>							
	n=2 (18%)	11	20.7	12.7	1.17E+04	20.7	0	
		12	21.6	21.6	2.38E+04	22.6	4.30E+03	
		13	23.7	23.7	5.80E+05	23.7	5.11E+05	
		14	21.0	15.0	3.56E+07	21.0	1.57E+05	
		15	19.1	19.7	1.10E+06	19.7	6.10E+04	
	<b>Groupe D</b>							
	n=1 (4%)	16	21.1	21.1	5.75E+06	21.1	2.25E+06	
			Moyenne	21.0	15.8	Médiane	1.31E+06	
			DS	2.5	5.5	Min	1.17E+04	
					Max	Max	1.70E+08	
ID Issue défavorable n=11 (41%)	<b>Groupe E</b>							
	n=2 (7%)	17	17.1	17.1	2.30E+05	19.9	1.03E+07	
		18	19.7	14.7	4.80E+03	20.0	2.88E+03	
	<b>Groupe F</b>							
	n=1 (4%)	19	21.1	16.9	1.27E+06	21.1	8.14E+03	
	<b>Groupe G</b>							
	n=8 (30%)	20	22.3	14.3	1.08E+07	22.3	6.03E+02	
		21	20.7	20.7	2.94E+06	21.9	0	
		22	22.1	22.1	2.01E+07	22.6	1.10E+05	
		23	18.3	13.3	4.80E+06	20.3	1.70E+06	
		24	21.6	21.6	2.50E+07	21.6	3.80E+05	
		25	21.1	20.1	1.66E+07	21.1	2.27E+04	
		26	19.9	16.9	2.30E+05	19.9	7	
		27	20.1	15.1	2.50E+06	20.1	8.92E+04	
			Moyennes	20.4	17.5	Médiane	2.94E+06	
			DS	1.6	3.1	Min	4.80E+03	
					Max	Max	2.50E+07	
	<b>Mann-Whitney</b>				P=0.55		P=0.82	

<sup>a</sup> âge de la grossesse en semaines de gestations (SG)

en rouge sont indiquées les valeurs >90ème percentile de toutes les charges virales

Annexe 2 : Tableau présentant les charges virales dans le liquide amniotique et le sang dans les deux groupes d'issue principaux.  
DS, déviation standard

	OF Outcome favorable n= 16 (59%)	OD Outcome défavorable n=11 (41%)
<b>Age maternel</b>		
à l'intervention	moyenne DS	32.19 5.26
		28.36 7.21
		primigeste 4/11 (36%)
<b>Gestité</b>	2ème grossesse 13/16 (81%)	2ème grossesse 7/11 (64%)
	3ème grossesse 3/16 (19%)	
		nullipare 3/16 (19%)
		nullipare 5/11 (45%)
<b>Parité</b>	primipare 12/16 (75%)	primipare 6/11 (55%)
	2 enfants 1/16 (6%)	
<b>période de l'infection maternelle</b>	périconceptionnelle <sup>a</sup> 6/16 (37%)	périconceptionnelle <sup>a</sup> 5/11 (45%)
	précoce <sup>b</sup> 10/16 (63%)	précoce <sup>b</sup> 6/11 (55%)

DS, déviation standard

<sup>a</sup> Date des dernières règles +4sem

<sup>b</sup> < 20 semaines de gestation

Annexe 3 : Comparaison des données maternelles dans les groupes d'issue principal.